Bb Biotech Ag Stake in Celgene Corp (CELG) Lowered as Stock Value Declined

January 19, 2018 - By Migdalia James

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.17, from 1.34 in 2017Q2. It is negative, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Sky Invest Group Ltd Liability reported 5,370 shares or 0.32% of all its holdings. Colony Gru Lc invested in 3,767 shares or 0.04% of the stock. Livforsakringsbolaget Skandia Omsesidigt accumulated 58,510 shares. Renaissance Ltd accumulated 1.25% or 248,722 shares. New York-based Laurion Capital Mngmt Lp has invested 0% in Celgene Corporation (NASDAQ:CELG). Messner & Smith Theme Value Investment Mgmt Limited Ca stated it has 3,447 shares or 0.79% of all its holdings. Zacks Investment Mgmt reported 2,042 shares. 7,814 were reported by First Heartland Consultants. Hikari Power Ltd has 57,400 shares. Bankshares Of The West invested in 0.13% or 6,943 shares. Moreover, Highlander Capital Limited Com has 0.34% invested in Celgene Corporation (NASDAQ:CELG). Moreover, Matarin Capital Mgmt Lc has 0.4% invested in Celgene Corporation (NASDAQ:CELG). Ing Groep Nv invested in 0.01% or 3,003 shares. Waddell & Reed Incorporated holds 0.75% or 2.33M shares. Lincoln National holds 0.04% or 7,314 shares.

Since August 2, 2017, it had 0 insider buys, and 5 insider sales for $6.27 million activity. CASEY MICHAEL D had sold 9,250 shares worth $1.29 million. Another trade for 1,727 shares valued at $248,498 was sold by Curran Terrie. 7,500 shares valued at $1.01 million were sold by KAPLAN GILLA on Wednesday, August 2.

Bb Biotech Ag decreased its stake in Celgene Corp (CELG) by 2% based on its latest 2017Q3 regulatory filing with the SEC. Bb Biotech Ag sold 65,000 shares as the company’s stock declined 3.49% while stock markets rallied. The institutional investor held 3.18M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $464.33 million, down from 3.25 million at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $80.09B market cap company. The stock decreased 0.29% or $0.3 during the last trading session, reaching $101.72. About 9.28 million shares traded or 8.30% up from the average. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since January 19, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Bb Biotech Ag, which manages about $3.61B US Long portfolio, upped its stake in Incyte Corp. (NASDAQ:INCY) by 153,500 shares to 3.67 million shares, valued at $428.24 million in 2017Q3, according to the filing. It also increased its holding in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 25,000 shares in the quarter, for a total of 205,000 shares, and has risen its stake in Esperion Therapeutics Inc. (NASDAQ:ESPR).

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 25. They expect $1.75 earnings per share, up 24.11 % or $0.34 from last year’s $1.41 per share. CELG’s profit will be $1.38B for 14.53 P/E if the $1.75 EPS becomes a reality. After $1.78 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69 % negative EPS growth.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Celgene: Impact Biomedicines To Broaden The Pipeline” on January 09, 2018, also Seekingalpha.com with their article: “Celgene – Strong Portfolio Should Support Growing Earnings” published on January 09, 2018, Investorplace.com published: “Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive” on January 19, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Fool.com and their article: “Here’s Where Things Went Wrong for Celgene Corporation in 2017” published on December 29, 2017 as well as Finance.Yahoo.com‘s news article titled: “Is Celgene (CELG) Looking to Take Over Juno Therapeutics?” with publication date: January 17, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. Celgene Corporation had 124 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was initiated by Stifel Nicolaus on Friday, July 15 with “Buy”. BMO Capital Markets maintained it with “Outperform” rating and $167 target in Tuesday, October 17 report. The stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by Argus Research on Friday, May 5. BMO Capital Markets maintained the shares of CELG in report on Friday, November 17 with “Outperform” rating. The stock of Celgene Corporation (NASDAQ:CELG) has “Underweight” rating given on Monday, October 23 by Morgan Stanley. Jefferies initiated Celgene Corporation (NASDAQ:CELG) rating on Monday, July 10. Jefferies has “Buy” rating and $16000 target. The company was maintained on Friday, July 28 by BMO Capital Markets. Oppenheimer maintained it with “Buy” rating and $14800 target in Wednesday, June 7 report. The company was maintained on Friday, October 27 by BMO Capital Markets. On Thursday, October 19 the stock rating was maintained by RBC Capital Markets with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.